<DOC>
	<DOCNO>NCT02262260</DOCNO>
	<brief_summary>To explore clinical feasible treatment regime ranibizumab DME provide satisfactory treatment effect lower number visit injection .</brief_summary>
	<brief_title>Compare Safety/Efficacy Labeled vs Wait-Extend Regimen Lucentis Turkish Patients With VI Due DME</brief_title>
	<detailed_description>Diabetes mellitus ( DM ) common endocrine disease develop country , prevalence estimate range 2 5 % world 's population . Diabetic retinopathy ( DR ) diabetic macular edema ( DME ) common microvascular complication patient diabetes may sudden debilitate impact visual acuity ( VA ) , eventually lead blindness . DME frequent manifestation DR major cause visual loss patient DR . If leave untreated , &gt; 50 % patient lose &gt; 2 line visual acuity ( VA ) within 2 year . DME mostly affect working-age population , impose significant burden society individual patient - burden expect increase rise prevalence diabetes .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . M F patient &gt; 18 year age sign informed consent Patients Type 1 Type 2 DM ( accord ADA WHO guideline ) HbA1c 12.0 % screening ( Visit 1 ) . Patients diet , exercise , and/or pharmacological treatment diabetes . Patients visual impairment due focal diffuse macular edema center involvement least one eye , demonstrate color fundus photography , fluorescein angiography OCT within 28 day baseline treatment . If eye eligible , one bad visual acuity , assess Visit 1 , select study treatment unless , base medical reason , investigator deems eye appropriate candidate study treatment . The study eye must fulfill follow criterion Visit 1 : BCVA score 78 39 letter , inclusively , use ETDRSlike visual acuity test chart test distance 4 meter ( approximate Snellen equivalent 20/32 20/160 ) Decrease vision due DME due cause , opinion investigator Exclusion Criteria Concomitant condition study eye accord define criterion infection , inflammation , uncontrolled glaucoma Active PDR study eye evidence vitreomacular traction either eye Patients monocular BCVA score nonstudy eye ( fellow eye ) Â£ 24 letter Visit 1 Concomitant systemic condition accord define criterion , eg . history stroke , uncontrolled diabetes , renal failure , unsatisfactory control hypertension Use investigational drug within 5 halflives enrollment , within 30 day expect PD effect return baseline , whichever longer . History hypersensitivity study drug drug similar chemical class . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic macular edema , DME , ranibizumab , wait extend</keyword>
</DOC>